Lir Life SciencesBBCMF -80.00%15 EV-to-FCF is -5.56 as of Jun. 24, 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 328 Biotechnology companies, Lir Life Sciences ranks worse than 304877.74% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lir Life Sciences's Enterprise Value is $7.31 Mil.
Lir Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 was $-1.32 Mil. Therefore, Lir Life Sciences's EV-to-FCF for today is -5.56.
The historical rank and industry rank for Lir Life Sciences's EV-to-FCF or its related term are showing as below:
BBCMF'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.56 Med: 0 Max: 0
Current: -5.56
BBCMF's EV-to-FCF is ranked worse than 100% of 328
companies
in the Biotechnology industry
Industry Median: 14.86
vs BBCMF: -5.56
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lir Life Sciences (OTCPK:BBCMF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lir Life Sciences's PE Ratio (TTM) for today is calculated as:
Lir Life Sciences's share price for today is $0.05.
Lir Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lir Life Sciences EV-to-FCF Related Terms
Lir Life Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Lir Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lir Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lir Life Sciences EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lir Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lir Life Sciences's EV-to-FCF falls into.
Lir Life Sciences's current Enterprise Value is $7.31 Mil.
Lir Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lir Life Sciences (BBCMF) has a EV-to-FCF of -5.56 as of Jun. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #999999 out of 328 companies in the Biotechnology industry.
Is Lir Life Sciences' EV-to-FCF too high?
Lir Life Sciences' current EV-to-FCF is -5.56. Based on the distribution chart, Lir Life Sciences ranks #999999 out of 328 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #999999 out of 328 companies for EV-to-FCF. This places Lir Life Sciences in the lower half of its industry. The industry median EV-to-FCF is 14.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.86, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lir Life Sciences and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current EV-to-FCF is -5.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current EV-to-FCF of -5.56. The current EV-to-FCF is -5.56. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current EV-to-FCF is -5.56 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score
Get the complete analysis for BBCMF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBCMF has been successfully added to your 